Rapid infusion of second dose rituximab appears safe
the ONA take:
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication in an experienced outpatient infusion center as long as patients are appropriately screened, according to a new study published online ahead of print in the journal Supportive Care in Cancer.
For the study, researchers enrolled 50 patients with indolent and intermediate B-cell non-Hodgkin's lymphoma receiving rituximab treatment at The Ohio State Comprehensive Cancer Center-James Cancer Hospital in Columbus, Ohio.
All patients had received the first dose of rituximab according to the manufacturer-labeled standard titration schedule and had not experienced a grade 2 or higher infusion reaction. Participants then received the subsequent infusion without steroid premedication at 100 mg/hour over 15 minutes, with the remaining amount administered over 45 minutes.
Results showed that no infusion-related reactions occurred with the 60-minute rapid infusion protocol.
Researchers found that an average of about 94 minutes were saved with rapid infusion compared with the standard second dose infusion recommendation. Moreover, oncology nurses reported 100% satisfaction with the rapid infusion protocol.
The findings suggest that rapid infusions can reduce resource utilization and improve nursing satisfaction.
Subsequent rituximab infusions can be safely administered over 60 minutes and without steroid premedication.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Prognostic Factors for Survival Among Patients With Primary Bone Sarcomas of Small Bones
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- A Call for More Tailored Cancer Education Programs to Improve Screening
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|